Clinical Characteristics and Therapeutic Effects of Checkpoint Inhibitor-Related Pneumonitis in Patients with Non-Small Cell Lung Cancer

Abstract

Abstract Background: With the application of immune checkpoint inhibitors (ICIs) in cancer treatment, more and more attention has been paid to checkpoint inhibitor-related pneumonitis (CIP), which requires a better understanding of its clinical characteristics and therapeutic effects. Methods: The clinical data of 704 patients with non-small cell lung cancer (NSCLC) who received immunotherapy were analyzed retrospectively; the clinical and imaging data were analyzed; the clinical characteristics of CIP were summarized, and the therapeutic regimens and effects of the patients were summarized. Results: 36 CIP patients were included in the research. The most common clinical symptoms were cough, shortness of breath and fever. The CT manifestations were summarized as follows: Organizing pneumonia (OP) in 14 cases (38.9%) , nonspecific interstitial pneumonia (NSIP) in 14 cases (38.9%) , hypersensitiviy pneumonitis(HP) in 2 cases (6.3%) , diffuse alveolar damage in 1 case (3.1%) and atypical imaging anifestations in 5 cases (13.9%). 35 cases received glucocorticoid therapy, 6 patients were treated with gamma globulin and 1 patient was treated with tocilizumab. There were no deaths in CIP G1-2 patients and 7 deaths occured in CIP G3-4 patients. 4 patients were treated again with ICIs. Conclusion: We found that glucocorticoid 1-2 mg/kg was effective for most patients with moderate to severe CIP, and a few patients with hormone insensitivity needed early immunosuppressive therapy. A few patients can be rechallenged with ICIs, but CIP recurrence needs to be closely monitored.